Combining immune checkpoint inhibitors with targeted therapies such as CDK4/6 inhibitors or PI3K inhibitors has shown potential in overcoming immune evasion and improving treatment efficacy in HR+ breast cancer. This evidence concerns the gene CDK4 and breast carcinoma.